Molecular imaging for the early diagnosis and monitoring of Alzheimer’s disease in old individuals with cognitive disturbances: an ADNI-compatible prospective study - 09/2011 Molecular Imaging

IRCCS CENTRO SAN GIOVANNI DI DIO0 个研究点开始时间: 2012年3月1日最近更新: 2013年12月23日

适应症

试验速览

暂无简介。

•-Male and female aged between 55-90 years; -Memory complains reflecting a change in cognition reported by patient or informant or clinician; -Presence of objective memory or other cognitive domain impairment; -General cognition and functional performance sufficiently preserved such that a diagnosis of Alzheimer’s disease cannot be made by the site physician at the time of the screening visit; -Mini-Mental State Exam score between 24 and 30 (inclusive); -Clinical Dementia Rating = 0.5. Memory Box score must be at least 0.5; -Amnestic Mild Cognitive Impairment (MCI) (pure amnestic or multidomain); -At least 5 grades education. -Written informed consent
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 15
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 85

•-Visual and auditory acuity inadequate for neuropsychological testing; -History of significant neurological or psychiatric illnesses or presence of other diseases precluding enrolment; -The chronic use of anti-inflammatory drugs -Female subjects of child-bearing potential with a positive pregnancy test; -Female subjects who are nursing;

发起方

IRCCS CENTRO SAN GIOVANNI DI DIO